Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Terapevticheskii Arkhiv|April 16, 2025
[Evolution of enterology as a science]E A Sabelnikova, A V Kagramanova, O V Knyazev, et al.Terapevticheskii Arkhiv|May 17, 2019
The use of fecal calprotectin in monitoring activity of inflammatory bowel diseasesO V Knyazev, A V Kagramanova, I A Korneeva, et al.Terapevticheskii Arkhiv|February 1, 2019
Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practiceO V Knyazev, A V Kagramanova, A A Lishchinskaya, et al.Terapevticheskii Arkhiv|October 26, 2022
[Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy]O V Knyazev, S G Khomeriki, A V Kagramanova, et al.Terapevticheskii Arkhiv|May 3, 2016
[Current principles in the screening, diagnosis, and therapy of colorectal cancer]I E Khatkov, A V Kagramanova, N B Zakharzhevskaya, et al.Terapevticheskii Arkhiv|December 30, 2023
[Tuberculosis infection in patients with inflammatory bowel diseases. Clinacal cases]M U Timanovskaia, Y R Shaykhtdinova, E U Zhulina, et al.Terapevticheskii Arkhiv|April 16, 2025
[Prevention of venous thromboembolic complications in patients with ulcerative colitis]A A Lishchinskaya, O V Knyazev, A V Kagramanova, et al.Terapevticheskii Arkhiv|February 1, 2019
Stem Cell Therapy for Perianal Crohn's DiseaseO V Knyazev, N A Fadeeva, A V Kagramanova, et al.Terapevticheskii Arkhiv|October 26, 2022
[Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn's disease when switching from the original infliximab to its biosimilars]O V Knyazev, M Y Zvyaglova, A V Kagramanova, et al.Terapevticheskii Arkhiv|June 30, 2020
[Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation]O V Knyazev, T V Shkurko, A V Kagramanova, et al.Pageof 3